Mydicar
Phase 2- Indications
- Cardiovascular disease
Company intelligence / Profile preview
Theragene Pharmaceuticals
San Diego, California, United Statestheragenepharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Currently developing SERCA 2a gene therapy (Mydicar®) for heart failure and cardiomyopathies. Phase I/II trials have demonstrated safety and efficacy, with recent enrollment completion in the MUSIC-HFrEF trial as of March 2025[8][9].
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Gene therapyImmunotherapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
SardocorEiger BioPharmaceuticals (acquired Mydicar® from them)
Beyond the preview
Go deeper on Theragene Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theragene Pharmaceuticals.